Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc at Stifel CNS Day Transcript

Apr 01, 2021 / 04:00PM GMT
Release Date Price: $45.05 (+0.20%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks so much, everybody. It's my pleasure to be hosting this panel with Frank Bennett, an R&D leader at Ionis, and also one of the experts in neuroscience and neurology drug development. And he's been kind enough to join this conference every year. So I really appreciate it, Frank, for you coming today.

On that note, I was maybe just kind of hoping you could start, Frank, and give an overview of the various clinical-stage assets that Ionis has in development for CNS. And then naturally, we can get into Q&A and more of a discussion. So thanks again.

C. Frank Bennett
Ionis Pharmaceuticals, Inc. - Executive VP & Chief Scientific Officer

Well, my pleasure, and thank you for inviting me to participate. Yes, so we have a rich and growing pipeline of CNS drugs. To date, we have 2 approved drugs with -- and 9 drugs currently in clinical development, and a rich pipeline of preclinical drugs.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot